Table 3.
Tumor features of meningiomas in included clinical trials
| First author (year) | Drug | Histology* | Location* | Grade* | Receptors tested |
Confirmed receptor positive (% cohort) |
Receptor detection method |
|---|---|---|---|---|---|---|---|
| Markwalder (1985) [47] | Tamoxifen | 1 fibrous | 1 skull base; 1 parasagittal | Not specified | 1 | 0 | Not specified |
| Goodwin (1993) [48] | Tamoxifen | Not specified | Not specified | Not specified | 1 | 0 | Not specified |
| Grunberg (1990) [50] | Megestrol acetate | 6 meningothelial; 2 fibrous; 1 anaplastic | 8 skull base; 1 convexity | 8 WHO I; 1 WHO III | 2 | 0 | Not specified |
| Grunberg (2006) [51] | Mifepristone 14-day course of dexamethasone 1 mg | 13 meningothelial | 22 skull base; 4 spinal; 2 convexity | 13 WHO I;2 WHO III | 0 | 0 | NA |
| Touat (2014) [52] | Mifepristone | 1 transitional | 3 multifocal | 1 WHO I | 3 | 1 (33% cohort; 100% assessed) | IHC‡ |
| Ji (2015) [42] | Mifepristone | 17 atypical | Not specified | 17 WHO II | 84 | 75 (46% cohort; 89% assessed) | IHC‡ |
| Chamberlain (2007) [56] | Octreotide (Sandostatin LAR) | Not specified | 7 skull base; 6 convexity; 3 multifocal | 8 WHO I; 3 WHO II; 5 WHO III | 16 | 16 (100%) | Radioimaging |
| Norden (2015) [57] | Octreotide (pasireotide LAR) | Not specified | Not specified | 18 WHO I; 18 WHO II/III | 34 | 34 (100%) | IHC‡ |
| Hrachova(2020) [58] | Octreotide (sandostatin LAR) | 5 atypical 6 anaplastic | 23 skull base; 15 convexity; 5 mixed | 32 WHO I; 5 WHO II; 6 WHO III | 43 | 43 (100%) | Radioimaging |
‡
Immunohistochemistry
*
The sum may not add up to total patients as information only given for tumors specified in studies, which frequently did not specify histology, location, and grade for every tumor